Ask AI

Capsule Summary Slidesets


Share

Program Content

Activities

  • Axatilimab Response Analysis
    AGAVE-201 Response Analysis: Axatilimab for Patients With Chronic GVHD
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 09, 2024

  • Pimicotinib in cGVHD
    Phase II Trial of Pimicotinib, a CSF-1R Inhibitor, for Previously Treated Chronic GVHD
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 10, 2024

  • LUNA 3: Rilzabrutinib in ITP
    LUNA 3: Phase III Trial of Rilzabrutinib vs Placebo in Patients Aged ≥18 Yr With Persistent/Chronic Primary ITP
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 11, 2024

  • VAYHIT3 Trial of Ianalumab
    Phase II VAYHIT3 Interim Results: Ianalumab in Previously Treated Primary Immune Thrombocytopenia 
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 11, 2024

  • ELA026 in sHLH
    Phase Ib Study of ELA026, an Anti-SIRP-α/β/γ mAb, in Patients With Secondary Hemophagocyctic Lymphohistiocytosis
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 13, 2024

  • Rovadicitinib in Chronic GVHD
    Updated Results From a Phase Ib/IIa Trial of Rovadicitinib for Glucocorticoid-Refractory or Dependent Chronic Graft-vs-Host Disease
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 16, 2024

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC.

Supporters

This educational activity is supported by independent medical educational grants from AstraZeneca, Bristol Myers Squibb, GlaxoSmithKline, Incyte Corporation, Lilly, and Novartis Pharmaceuticals Corporation.

AstraZeneca

Bristol Myers Squibb

GlaxoSmithKline

Incyte Corporation

Lilly

Novartis Pharmaceuticals Corporation